PRINCETON, N.J. — Bristol Myers Squibb has announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. Dr. Massacesi will join the company’s Executive Leadership Team and oversee both early- and late-stage product development across all therapeutic areas.
Dr. Massacesi brings more than two decades of global biopharmaceutical experience to the role, most recently serving as Chief Medical Officer of AstraZeneca and Alexion, and as Oncology Chief Development Officer at AstraZeneca. During his tenure, he led a team of more than 3,000 employees and advanced over 150 clinical studies, securing multiple regulatory approvals. His earlier experience includes senior R&D roles at Pfizer and Novartis, with a focus on oncology and hematology.
“We are thrilled to welcome Cristian to Bristol Myers Squibb,” said Christopher Boerner, Ph.D., Board Chair and CEO. “His deep scientific expertise, strong focus on clinical execution, and proven track record of regulatory success will be instrumental as we advance our pipeline and deliver breakthrough medicines to more patients worldwide.”
Dr. Massacesi, who began his career as a medical oncologist, emphasized the patient-centered nature of his work. “I am on a mission to discover new medicines—unlocking innovative approaches to researching and treating challenging diseases so that one day, no patient will hear that all options have been exhausted,” he said. “I am excited to join BMS in this shared purpose, with its storied history, vast pipeline, and deep commitment to making a difference.”
The appointment coincides with the planned departure of Samit Hirawat, M.D., who has served as Bristol Myers Squibb’s Chief Medical Officer and Head of Development for the past six years. Dr. Hirawat will step down from his role on August 1 and will remain with the company in an advisory capacity until November 1 to ensure a smooth transition.
“We sincerely thank Samit for his leadership and dedication over the past six years,” Boerner said. “Under his guidance, we achieved multiple product approvals and advanced innovative therapies across oncology, hematology, immunology, cardiovascular, and neuroscience.”
Dr. Massacesi will be based at Bristol Myers Squibb’s headquarters in Princeton, New Jersey, and report directly to Boerner.
